4D Molecular Therapeutics... (FDMT)

NASDAQ: FDMT · Real-Time Price · USD

3.44

0.07 (2.08%)

At close: May 01, 2025, 3:59 PM

3.47

1.02%

After-hours: May 01, 2025, 06:55 PM EDT

2.08% (1D)

Bid	3.44
Market Cap	159.05M
Revenue (ttm)	37K
Net Income (ttm)	-160.87M
EPS (ttm)	-2.98
PE Ratio (ttm)	-1.15
Forward PE	-0.89
Analyst	Buy

Ask	3.48
Volume	507,747
Avg. Volume (20D)	810,790
Open	3.50
Previous Close	3.37
Day's Range	3.27 - 3.45
52-Week Range	2.23 - 28.93
Beta	2.88

About FDMT

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Dec 11, 2020

Employees 227

Stock Exchange NASDAQ

Ticker Symbol FDMT

Website https://www.4dmoleculartherapeutics.com

Full Company Profile

Analyst Forecast

According to 8 analyst ratings, the average rating for FDMT stock is "Buy." The 12-month stock price forecast is $35.5, which is an increase of 933.48% from the latest price.

Stock Forecasts

Next Earnings Release

4D Molecular Therapeutics Inc. is scheduled to release its earnings on May 16, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

-13.91%

4D Molecular Therapeutics shares are trading lower... Unlock content with Pro Subscription

3 months ago

-13.77%

4D Molecular Therapeutics shares are trading lower after Leerink Partners and Morgan Stanley cut their respective price targets on the stock.

News

2 months ago · seekingalpha.com

4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression

4D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential to disrupt the anti-VEGF treatment paradigm for retinal diseases. The company has a strong cash position of $...

2 months ago · benzinga.com

Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study

On Saturday, 4D Molecular Therapeutics FDMT announced initial interim 52-week data from the Phase 2b Population Extension cohort of the PRISM trial of 4D-150 in a broad wet age-related macular degener...

2 months ago · accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ:FDMT). Such investor...